Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - methotrexat - injektionsvæske, opløsning i fyldt injektionssprøjte - 50 mg/ml

Uni Eropa - Dansk - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - ibandronsyre - hypercalcemia; breast neoplasms; neoplasm metastasis; fractures, bone - narkotika til behandling af knoglesygdomme - bondronat er indiceret til forebyggelse af skelet hændelser (patologiske frakturer, knogle komplikationer, som kræver strålebehandling eller operation) hos patienter med brystkræft og knoglemetastaser, behandling af tumor-induceret hypercalcaemia med eller uden metastaser.

Uni Eropa - Dansk - EMA (European Medicines Agency)

pharmathen s.a. - ibandronsyre - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - narkotika til behandling af knoglesygdomme - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. behandling af tumor-induceret hypercalcaemia med eller uden metastaser. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Uni Eropa - Dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - ibandronsyre - wounds and injuries; breast diseases; neoplastic processes; calcium metabolism disorders; water-electrolyte imbalance - narkotika til behandling af knoglesygdomme - ibandronic acid er angivet i voksne forprevention af skelet hændelser (patologiske frakturer, knogle komplikationer, som kræver strålebehandling eller operation) hos patienter med brystkræft og knoglemetastaser. behandling af tumor induceret hypercalcaemia med eller uden metastaser. behandling af osteoporose hos postmenopausale kvinder med øget risiko for fraktur (se afsnit 5. en reduktion af risikoen for vertebrale frakturer er blevet påvist, at effekten på lårbenshals brud er ikke blevet oprettet.

Uni Eropa - Dansk - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - palifermin - mucositis - alle andre terapeutiske produkter - kepivance er angivet til at reducere hyppigheden, varigheden og sværhedsgraden af oral mucositis hos voksne patienter med maligne hæmatologiske sygdomme modtager myeloablative radiochemotherapy forbundet med en høj forekomst af svær mucositis og kræver autolog-hæmatopoietisk-stamcelle-support.

Uni Eropa - Dansk - EMA (European Medicines Agency)

mylan pharmaceuticals limited - lopinavir, ritonavir - hiv infektioner - antivirale midler til systemisk anvendelse - lopinavir/ritonavir angives i kombination med andre antiretrovirale lægemidler til behandling af human immundefekt virus (hiv-1) inficeret voksne, unge og børn over 2 år. valget af lopinavir/ritonavir til at behandle proteasehæmmer oplevet hiv-1-inficerede patienter bør være baseret på individuelle viral resistens test og historie behandling af patienter.

Uni Eropa - Dansk - EMA (European Medicines Agency)

merck sharp and dohme b.v - ribavirin - hepatitis c kronisk - antivirals for systemic use, antivirals for treatment of hcv infections - rebetol er indiceret i kombination med andre lægemidler til behandling af kronisk hepatitis c (chc) hos voksne. rebetol er indiceret i kombination med andre lægemidler til behandling af kronisk hepatitis c (chc) for pædiatriske patienter (børn fra 3 år og ældre og unge), der ikke tidligere er behandlet, og uden leveren dekompensation.

Uni Eropa - Dansk - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 og 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

fresenius kabi ab - carboplatin - koncentrat til infusionsvæske, opløsning - 10 mg/ml

Denmark - Dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - fluvastatinnatrium - depottabletter - 80 mg